Compass Therapeutics (CMPX) Equity Average (2018 - 2026)

Compass Therapeutics has disclosed Equity Average across 9 years of filings, most recently posting $191.6 million for Q1 2026.

• Equity Average for Q1 2026 came in at $191.6 million, up 62.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $191.6 million (up 62.74% YoY), and the FY2025 annual result was $161.0 million, up 17.63% from the prior year.
• Equity Average came in at $191.6 million for Q1 2026 at Compass Therapeutics, down from $203.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $203.2 million in Q4 2025 to a low of $101.7 million in Q2 2025.
• The 5-year median for Equity Average is $151.4 million (2025), against an average of $150.1 million.
• Across the five-year window, Equity Average jumped 273.99% in 2022 and tumbled 32.88% in 2025, its largest moves.
• Compass Therapeutics' Equity Average stood at $148.9 million in 2022, then gained by 3.64% to $154.3 million in 2023, then declined by 14.57% to $131.8 million in 2024, then soared by 54.16% to $203.2 million in 2025, then declined by 5.69% to $191.6 million in 2026.
• The last three Equity Average figures came in at $191.6 million (Q1 2026), $203.2 million (Q4 2025), and $151.4 million (Q3 2025), per Business Quant data.